Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

This study is testing whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a liver-targeted radiation treatment (Y-90 SIRT, where tiny radioactive beads are injected into blood vessels feeding the tumor) can improve outcomes for people with intermediate-stage liver cancer. **You may be eligible if...** - You are 18 or older and weigh more than 30 kg - You have liver cancer (hepatocellular carcinoma) that has multiple nodules or is a large single tumor, and cannot be removed surgically - Your liver function is relatively preserved (Child-Pugh A) - You have not yet received systemic (whole-body) treatment for liver cancer **You may NOT be eligible if...** - Your cancer has spread beyond the liver to other organs - You have autoimmune diseases that require treatment - Your liver function is severely compromised Talk to your doctor to see if this trial is right for you.